Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2023; 11(14): 3356-3361
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3356
Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report
Cai-Bao Jin, Ling Yang
Cai-Bao Jin, Ling Yang, Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan 430000, Hubei Province, China
Author contributions: Jin CB performed the research and wrote the paper; Yang L supervised the report.
Informed consent statement: Patient was not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ling Yang, MD, Chief Doctor, Department of Thoracic Oncology, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Wuhan 430000, Hubei province, China. 348711624@qq.com
Received: March 2, 2023
Peer-review started: March 2, 2023
First decision: March 24, 2023
Revised: April 2, 2023
Accepted: April 7, 2023
Article in press: April 7, 2023
Published online: May 16, 2023
Processing time: 74 Days and 18.8 Hours
Abstract
BACKGROUND

Bladder metastasis from lung cancer with epidermal growth factor receptor (EGFR) mutation is extremely rare. Here, we report a case of bladder metastasis from lung adenocarcinoma with EGFR mutation.

CASE SUMMARY

A 53-year-old female patient was diagnosed with advanced lung adenocarcinoma with EGFR exon 19 deletion. Multiple nodules on the bladder wall were found by regular examination of the pelvic cavity through computed tomography during targeted therapy. Further cystoscopy and histological examination of bladder biopsy tissues confirmed the bladder metastasis from lung adenocarcinoma. In addition, genetic analysis of the bladder metastasis revealed EGFR T790M mutation. The patient achieved a good response to a third-generation EGFR tyrosine kinase inhibitor.

CONCLUSION

During routine follow-up of lung cancer patients, imaging examination of the pelvic cavity should be performed to avoid missing bladder metastasis. The ultimate diagnosis of bladder metastasis sill depends on the pathological result of biopsy tissues.

Keywords: Bladder metastasis; Lung cancer; EGFR mutation; Tyrosine kinase inhibitor; Histological examination; Case report

Core Tip: Bladder metastasis from lung cancer with epidermal growth factor receptor (EGFR) mutation is extremely rare. We reported a case of bladder metastasis from lung adenocarcinoma with EGFR mutation. During routine follow-up of lung cancer patients, imaging examination of the pelvic cavity should be performed to avoid missing bladder metastasis. The ultimate diagnosis of bladder metastasis sill depends on the pathological result of biopsy tissues as determined by cystoscopy. Bladder metastasis with EGFR mutation seems to respond well to the treatment of EGFR tyrosine kinase inhibitors.